Tandem Diabetes Care (NASDAQ:TNDM) Announces Earnings Results

Tandem Diabetes Care (NASDAQ:TNDM) issued its earnings results on Thursday. The medical device company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.16, FiscalAI reports. Tandem Diabetes Care had a negative net margin of 20.17% and a negative return on equity of 68.23%. The business had revenue of $247.22 million for the quarter, compared to analysts’ expectations of $240.41 million. During the same quarter in the previous year, the firm posted ($0.66) EPS. The business’s revenue for the quarter was up 5.5% compared to the same quarter last year.

Here are the key takeaways from Tandem Diabetes Care’s conference call:

• Tandem reported strong Q1 results with more than 29,000 pump shipments and $247 million in sales, and management is reaffirming 2026 guidance.
• The company has begun its PayGo pharmacy rollout, achieving ~40% formulary coverage early and <5% initial pharmacy ordering, a strategic shift management says will raise ASPs and margins as execution scales.
• Product momentum accelerated: Mobi now supports Android in the U.S., Control‑IQ+ cleared for use in pregnancy (first AID cleared for pregnancy in the U.S.), Libre 3 Plus and Dexcom G7 integrations planned, international Mobi launch in Q2, and a Mobi Tubeless 510(k) filing and a pivotal fully closed‑loop study are on track.
• Infusion set supplier shortages created modest supply‑sales pressure and meaningful customer impact for affected SKUs, with the company expecting disruption to persist into Q2 and some $3M–$4M timing headwinds from the international go‑direct transition.
• Margins and balance sheet strengthened: Q1 non‑GAAP gross margin was 55% (a Q1 record), adjusted EBITDA improved, the company generated $5M free cash flow and ended the quarter with $570M in cash (including $276M net proceeds from convertible debt), supporting execution of strategy.

Tandem Diabetes Care Trading Up 2.4%

Shares of TNDM stock opened at $18.47 on Friday. The firm’s 50 day moving average is $21.32 and its 200 day moving average is $20.33. The stock has a market capitalization of $1.27 billion, a P/E ratio of -6.02 and a beta of 1.64. Tandem Diabetes Care has a 12-month low of $9.98 and a 12-month high of $29.65. The company has a current ratio of 2.55, a quick ratio of 2.02 and a debt-to-equity ratio of 2.00.

Analyst Ratings Changes

TNDM has been the subject of several recent analyst reports. Stifel Nicolaus upped their price objective on shares of Tandem Diabetes Care from $20.00 to $22.00 and gave the company a “hold” rating in a research note on Friday, February 20th. Piper Sandler raised shares of Tandem Diabetes Care from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $21.00 to $33.00 in a research note on Tuesday, March 17th. Mizuho set a $22.00 price target on shares of Tandem Diabetes Care and gave the stock a “neutral” rating in a research note on Friday, February 20th. The Goldman Sachs Group decreased their price target on shares of Tandem Diabetes Care from $28.00 to $25.00 and set a “neutral” rating for the company in a research note on Thursday, April 9th. Finally, Truist Financial raised shares of Tandem Diabetes Care from a “hold” rating to a “buy” rating and increased their price target for the stock from $27.00 to $35.00 in a research note on Thursday, March 19th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $30.05.

Institutional Trading of Tandem Diabetes Care

Hedge funds have recently bought and sold shares of the stock. Smartleaf Asset Management LLC lifted its stake in Tandem Diabetes Care by 80.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,330 shares of the medical device company’s stock worth $30,000 after purchasing an additional 593 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its holdings in shares of Tandem Diabetes Care by 200.0% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,205 shares of the medical device company’s stock worth $27,000 after buying an additional 1,470 shares during the last quarter. Van ECK Associates Corp grew its holdings in Tandem Diabetes Care by 67.4% during the 4th quarter. Van ECK Associates Corp now owns 3,430 shares of the medical device company’s stock valued at $75,000 after purchasing an additional 1,381 shares during the last quarter. Quarry LP grew its holdings in Tandem Diabetes Care by 2,597.1% during the 3rd quarter. Quarry LP now owns 3,695 shares of the medical device company’s stock valued at $45,000 after purchasing an additional 3,558 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its holdings in Tandem Diabetes Care by 218.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 9,168 shares of the medical device company’s stock valued at $171,000 after purchasing an additional 6,290 shares during the last quarter.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc (NASDAQ: TNDM), headquartered in San Diego, California, is a medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes. Founded in 2006, the company introduced its first product, the t:slim® Insulin Pump, in 2011 and has since built a portfolio of next-generation pumps featuring touchscreen interfaces, remote software updates and integrated continuous glucose monitoring (CGM) capabilities.

The company’s flagship offering, the t:slim X2® Insulin Pump, is engineered to work with leading CGM sensors and features automated insulin delivery algorithms that adjust basal insulin rates based on real-time glucose trends.